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which temozolomide, nimustine, doxorubicin, and teniposide
were most common. 53% of these patients received subsequent
chemotherapy regimens.forty-four percent (16/36) underwent
surgery initially for their recurrence, with 81% (13/16) of these
patients receiving subsequent chemotherapy. Other drugs used in
treatment of recurrent disease included doxorubicin and lomus-
tine. CONCLUSION: Consistent with published guidelines,
GBM patients in Germany with better functional status undergo
active therapy. Patients initially undergo surgery, followed by
radiotherapy. Chemotherapy is often used with or immediately
following radiotherapy or at disease recurrence.
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OBJECTIVES: This oncology-speciﬁc organization integrated
into its electronic medical record (EMR) system a series of clini-
cal pathways (CPs) based on national guidelines. The objective
was to to evaluate adherence to pathways and develop a pro-
cess for communication to practices regarding performance.
METHODS: The CPs are based on clinical and economic litera-
ture and are physician-led. Adherence is measured using a com-
bination of patient disease, stage of disease, and line of therapy.
A combination of methods has been used in the reporting
process, including web-based reports; involvement of staff phar-
macists to promote and monitor clinical pathway adherence at
the local level; multiple teleconferences among pharmacists and
physicians to discuss cases, share successes, failures, and ideas;
and inclusion of network pathway reports for all attendees at the
organization’s biannual national P&T meetings. RESULTS:
Eighteen practices have EMR pathway reporting capabilities,
with new practices being added every month. Currently clinical
pathways for 7 cancer types have been implemented into the
EMR system. Pharmacists have increased their role in promoting
pathway adherence. One of the greater challenges has not been to
improve pathway adherence per se, but to increase completion
of key elements of evaluation, including disease stage and line of
therapy. CONCLUSION: Early evaluation shows monitoring of
pathways can be conducted with use of an EMR. Regular feed-
back on missing data has encouraged providers to update clinical
data entry. The complexity and dynamic nature of oncology
treatment requires frequent evaluation of clinical pathways to
ensure they are current and are based on both clinical and
economic evidence.
CANCER—Methods and Concepts
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OBJECTIVES: Conventional cost-effectiveness analysis are
usually supported by clinical data collected in phase III RCTs
(Drummond, 2005) and it is typically based on time-to-event
data. However, ignoring mean quality-adjusted survival for mul-
tiple transitions may introduce some estimates bias. Multi-state
models appeared to eliminate some limitations of Q-TWiST
models such as the necessity for progressive states (Billingham,
1999), but the applicability of these models in heath economics is
still unclear. The aim of this analysis is to compare the results of
two modeling alternatives: conventional cost-effectiveness analy-
sis and multi-state cost-effectiveness analysis taking capecitabine
versus docetaxel in mBC in Brazil as a study case. METHODS:
Conventional and multi-state survival analysis techniques were
applied on O’Shaugnessy (2001) data to perform both cost-
effectiveness analysis. For the conventional survival analysis, a
Cox and parametric approach were used, and the best ﬁt was
chosen analyzing Cox-Snell and deviance residuals, as well as
AIC and BIC criteria. For multi-state survival analysis, the model
estimation was based on Gardiner (2006), and assumed as a
three-stage non-homogeneous Markov process. For costs, the
resource use was obtained from O’Shaugnessy trial and unit costs
were derived from published lists such as CBHPM 2004, Simpro
magazine and PROAHSA report. RESULTS: In conventional
analysis the incremental cost-effectiveness ratio (ICER) was
R$26,208 per QALY assuming log-logistic distributions which
was the best ﬁtted one, meanwhile in multi-state analysis, the
incremental cost-effectiveness ratio was R$19,320 per QALY
using weilbull distributions (Klein, 1994). PSA was performed
using Monte-Carlo simulations that supported the robustness
of the ﬁndings. CONCLUSION: Despite multi-state analysis
demands more sophisticated statistical background, there is an
evident superiority in multi-state estimates precision and accu-
racy when performing cost-effectiveness analysis. Regarding to
capecitabine, it was observed that in both models its addition in
this setting could be considered as a cost-effective alternative
under the private payer perspective in Brazil.
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OBJECTIVES: To investigate the impact of chronic lymphocytic
leukaemia (CLL) on health-related quality of life (HRQL) and
the gain in terms of descriptive richness associated with using an
EQ-5D with additional levels (EQ-5D-5L) in the CLL patient
population. METHODS: The EQ-5D-5L employed in this study
incorporates 5 levels of assessment but without additional label-
ling (Levels 2 and 4 are unlabeled). Our study involves a cohort
of patients with CLL from 19 participating Dutch centres.
Health-related quality of life (HRQL) is assessed at 6 monthly
intervals. The following analysis is based on the initial HRQL
assessment, which captured patients at various phases in their
disease course. RESULTS: In March 2006, 134 patients had
completed at least one EQ-5D-5L questionnaire of whom 63%
were male of median age 66 years. Median age for females was
higher at 70 years. Most patients (72%) were in remission at the
time of the ﬁrst HRQL assessment. Twenty-six percent selected at
least one alternative level on the EQ-5D-5L. The dimensions
where patients reported most problems were Pain/Discomfort
(level 1: 57%, level 2: 8%, level 3: 32%, level 4: 1%) and Usual
Activities (level 1: 62%, level 2: 7%, level 3: 28%, level 4: 2%,
level 5: 1%), followed by the Mobility dimension (level 1: 69%,
level 2: 8%, level 3: 22%). Few patients reported problems in
terms of Self-care (5%). The mean VAS score was 75.08
(SD = 14.3). Utility scores were 0.88 (SD = 0.15) for the EQ-5D-
5L, slightly higher than for the 3-level categorization at 0.84
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